Research & Education

Chemotherapy Options for Metastatic Lung Cancer - 13th Webinar: IASLC Lung Cancer Grand Rounds Series

March 11, 2015 at 9 p.m. EDT - Recording Available

 

   

Mark A. Socinski, MD
Professor of Medicine and Cardiothoracic Surgery
Director, Lung Cancer Section, Division of Hematology/Oncology
Clinical Associate Director, Lung SPORE
Co-Director, UPMC Lung Cancer Center of Excellence
Co-Leader, UPCI Lung Cancer Program

Ramaswamy Govindan, MD - Program Chair
Co-Director, Section of Medical Oncology
Professor of Medicine
Division of Oncology
Washington University School of Medicine

IASLC is holding a LIVE WEBINAR featuring Dr. Mark Socinski. During this live webinar, Dr. Socinski will address the issues and considerations relative to the selection of chemotherapy options for patients with advanced stage non-small cell lung cancer.

Name of Reviewer(s): 

              

Fred Hirsch, MD, PhD –Speakers Bureau/Advisory Board: Astrazeneca, Genentech, BMS, Lilly and Abbvie.

Name of Planner(s): 

 

     Deb Whippen-Nothing to Disclose

Name of Activity: 

 

Chemotherapy Options for Metastatic Lung Cancer

Date of Activity:

 

03/11/2015

Faculty/Speaker(s):

 

Mark A. Socinski, MD – Speaker

Dr Socinski Research was funded by Pfizer, Synta, BI, Celgene AZ, Genentech and Clovis. He is part of Advisory Board for Pfizer, Millenium. Speaker Bureau for Genentech and Celgene.

Ramaswamy Govindan, MD - Moderator/Program Chair- Pfizer: Advisory Board, Celgene: Advisory Board, AztraZeneca: Advisory Board, INC Research: Consulting, AbbVie: Consulting, Advisory Board and Honorarium, MSK: Advisory Board.

Type of Activity: 

 Live Course

  Internet Live Course (Webinar)XXXX

 Internet Enduring Material

Are there Commercial Supporters for this activity?

Yes

If yes, please list: Grant for this webinar received from Bristol Meyers Squibb, Celgene and Genentech

Following a brief didactic presentation, Dr. Socinski will present several case scenarios which will address:

  • Chemotherapy options for induction therapy of advanced stage disease
  • When to use targeted therapies alone or in combination with cytotoxic chemotherapy
  • The role of maintenance chemotherapy or maintenance targeted therapy
  • Treatment options in the second line setting and beyond

Following the presentation, there will be ample time for discussion and a question/answer session. Attendees will be able to submit questions and comments to Dr. Socinski via internet chat.

After attending this program, participants will:

  • Discuss chemotherapy and targeted therapy options for the treatment of patients with advanced stage non-small cell lung cancer
  • Recognize clinical and treatment issues to be considered when addressing complex case presentations
  • Illustrate the major clinical trials now underway in advanced stage NSCLC

IASLC Financial/Commercial Relationships and Conflicts of Interest Policy

IASLC Honoraria Policy

IASLC Commercial Support Agreement(LOA)

DOWNLOAD RECORDING

CME INFO:

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

 

Financial/Commercial Relationships DISCLOSURES

A Conflict of Interest (COI) is created and exists when individuals in a position to control the content of CME, or their spouses/partners, that have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells, or distributes health care goods or services consumed by, or used, on patients that benefits the individual in any financial amount and therefore, may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected. 

 This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

IASLC CME assures that the planners/reviewers/authors/faculty/moderators/peer reviewers et. al. conflicts of interest  were identified, reviewed and resolved from all individuals involved in the development  or able to influence and control the content of this CME activity; IASLC CME assures that disclosure is given prior to an educational activity being delivered to learners.  Any individual who failed or refused to disclose relevant financial relationships was disqualified from this CME activity and removed from any of IASLC CME activity presentation.

All commercial relationships and conflicts of interest that are identified are thoroughly vetted by IASLC Ethics Committee, CME Subcommittee, and Independent reviewer. COI will be evaluated by the Board of Directors of the IASLC for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. IASLC CME is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.

 

CREDIT STATEMENT

IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IASLC CME designates this Internet Live Course activity for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

GOAL & PURPOSE

The objective of this workshop was to;

  • Chemotherapy options for induction therapy of advanced stage disease
  • When to use targeted therapies alone or in combination with cytotoxic chemotherapy
  • The role of maintenance chemotherapy or maintenance targeted therapy
  • Treatment options in the second line setting and beyond

TARGET AUDIENCE

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

DISCLAMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Thank you for your participation.

If you are interested in obtaining the CME Credits for these sessions you must indicate this when you register for the program. CME credit is only available to attendees of the live webinar.

Location Local time Time zone UTC offset
New City (U.S.A. - New York) Wednesday, March 11, 2015 at 9:00:00 PM EDT UTC-4 hours
Denver (U.S.A. - Colorado) Wednesday, March 11, 2015 at 7:00:00 PM MDT UTC-6 hours
Chicago (U.S.A. - Illinois) Wednesday, March 11, 2015 at 8:00:00 PM CDT UTC-5 hours
Los Angeles (U.S.A. - California) Wednesday, March 11, 2015 at 6:00:00 PM PDT UTC-7 hours
São Paulo (Brazil - São Paulo) Wednesday, March 11, 2015 at 10:00:00 PM BRT UTC-3 hours
Paris (France) Thursday, March 12, 2015 at 2:00:00 AM CET UTC+1 hour
Hong Kong (Hong Kong) Thursday, March 12, 2015 at 9:00:00 AM HKT UTC+8 hours
Tokyo (Japan) Thursday, March 12, 2015 at 10:00:00 AM JST UTC+9 hours
Corresponding UTC (GMT) Thursday, March 12, 2015 at 01:00:00    

How to use the Time Zone Converter